Glaukos Corporation (GKOS)
NYSE · Common stock · Surgical & Medical Instruments & Apparatus
As of Oct 21, 2:16 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow GKOS in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on GKOS and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
GKOS at a glance
Key statistics
$10.23B
Market capitalization
- Previous close
- $173.43
- Open
- $173.13
- Day range
- $173.13 – $177.66
- Volume
- 366.7K
- Average volume (30 sessions)
- 943.9K
- Shares outstanding
- 58.98M
- Earnings per share
- $(3.19)
- Price / book
- 15.0
- Price / sales
- 16.7
- Beta (1 year, vs SPY)
- 0.72
Where the price sits in its year
52-week range
88% of the range
- Below the 52-week high
- -7.3%
- Above the 52-week low
- +142.8%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $163.40+6.1%
- 50-day average
- $171.96+0.9%
- 200-day average
- $138.14+25.5%
Between the conventional 30 and 70 bands.
+4.8%
1 week
+7.4%
1 month
+13.5%
3 months
+53.6%
Year to date
+99.0%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with GKOS
GKOS on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on GKOS.
See the plans →
Every planScreen names like GKOS
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on GKOS
Put GKOS on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on GKOS
See whether there is an open premium alert on GKOS, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
GKOS headlines
- Glaukos Stocks Rides on Strong Product Demand Amid Competition
Benzinga · Sep 11, 2024
- Truist lifts Glaukos shares target, highlights strong market position - Investing.com
Investing.com · Jul 16, 2024
- Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
Benzinga · May 2, 2024
- Analyst Ratings For Glaukos
Benzinga · Apr 8, 2024
- 5 Analysts Have This To Say About Glaukos
Benzinga · Mar 22, 2024
- Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
Benzinga · Dec 21, 2023
SEC Form 4, most recent first
Insider filings
Navratil Tomas
−888
CHIEF DEVELOPMENT OFFICER · Open-market sale
$145.57K · Oct 5, 2026
Navratil Tomas
−327
CHIEF DEVELOPMENT OFFICER · Open-market sale
$53.88K · Oct 5, 2026
Navratil Tomas
−312
CHIEF DEVELOPMENT OFFICER · Open-market sale
$51.67K · Oct 5, 2026
Navratil Tomas
−229
CHIEF DEVELOPMENT OFFICER · Open-market sale
$35.32K · Sep 25, 2026
Navratil Tomas
−136
CHIEF DEVELOPMENT OFFICER · Open-market sale
$20.77K · Sep 25, 2026
Navratil Tomas
−167
CHIEF DEVELOPMENT OFFICER · Open-market sale
$25.33K · Sep 25, 2026
Navratil Tomas
−1.1K
CHIEF DEVELOPMENT OFFICER · Open-market sale
$167.74K · Sep 25, 2026
Navratil Tomas
−191
CHIEF DEVELOPMENT OFFICER · Open-market sale
$31.74K · Sep 16, 2026
About Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
- Exchange
- NYSE
- Security
- Common stock
- Industry
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Aliso Viejo, CA
- Employees
- 1,094
- Listed since
- Jun 25, 2015
- Website
- glaukos.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.